Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome

Yu Zhang; Li-li Qian; Jian-ping Shen; Jun-fa Chen; Yan-ting Gao; Jing-jing Xiang; Bao-dong Ye; Yu-hong Zhou

doi:10.1007/s11655-016-2276-9

Your Location：

Home >

Browse articles >

Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome

Updated：2021-08-27

- Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome
- Chinese Journal of Integrative Medicine Vol. 23, Issue 6, Pages: 469-473(2017)
- Affiliations：
  
  Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China
- Author bio：
- Funds：
  
  Supported by Zhejiang Provincial Administration of Traditional Chinese Medicine Youth Talent Program (No. 2012ZQ010), China
- DOI：10.1007/s11655-016-2276-9
  CLC：
- Published：2017，
  
  Published Online：9 December 2016，
Scan for full text
Zhang, Y., Qian, Ll., Shen, Jp. et al. Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome., Chin. J. Integr. Med. 23, 469–473 (2017). https://doi.org/10.1007/s11655-016-2276-9

Yu Zhang, Li-li Qian, Jian-ping Shen, et al. Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome. [J]. Chinese Journal of Integrative Medicine 23(6):469-473(2017)
Zhang, Y., Qian, Ll., Shen, Jp. et al. Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome., Chin. J. Integr. Med. 23, 469–473 (2017). https://doi.org/10.1007/s11655-016-2276-9 DOI：

Yu Zhang, Li-li Qian, Jian-ping Shen, et al. Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome. [J]. Chinese Journal of Integrative Medicine 23(6):469-473(2017) DOI： 10.1007/s11655-016-2276-9.

摘要

To observe the influence of treatment based on Chinese medicine pattern identification on cellular immunophenotype of the myelodysplastic syndrome (MDS). Sixty patients with MDS were randomly and equally assigned to the treatment group and the control group using a randomized digital table. Thirty patients in each group included 3 risk levels (low

moderate and high risks) with each level 10 patients according to the international prognostic scoring system. The control group was given conventional therapy which was also used in the treatment group. While the treatment group was given Zuogui Pill (左归丸) and Yougui Pill (右归丸) for low risk patients; Qingwen Baidu Decoction (清瘟败毒饮) and Bazhen Decoction (八珍汤) for moderate risk patients; Gexia Zhuyu Decoction (膈下逐瘀汤) and Qinghao Biejia Decoction (青蒿鳖甲汤) combined with Shiquan Dabu Decoction (十全大补汤) for high risk patients. After the treatment

the differences of overall response rate and immunophenotype (CD13

CD14

CD15

CD33 and CD34) of each group were analyzed. The overall response rate of the treatment group was significantly higher than the control group in low risk and moderate risk patients (P=0.029)

there was no statistical differences of overall response rate between the treatment group and the control group in high risk patients (P=0.089). The expressions of CD13

CD14

CD33 and CD34 in all three risk levels of the treatment group were obviously decreased after the treatment

while CD15 in all three risk levels of the treatment group was obviously increased after the treatment (P<0.05 or P<0.01). Meanwhile

the difference values of CD13 and CD33 in low risk level of the treatment group

CD33 and CD34 in moderate risk level of the treatment group as well as CD34 and CD15 in high risk level of the treatment group

were all greater than the control groups and they were statistically significant (P<0.05 or P<0.01). It shows a better therapeutic effect if the MDS patients treated with Chinese medicine pattern identification in addition to conventional therapy. Since the treatment may inhibit the malignant clones and improve the dysmaturity of granulocyte differentiation

it is a feasible option in clinical practice.

Abstract

the differences of overall response rate and immunophenotype (CD13

CD14

CD15

CD33 and CD34) of each group were analyzed. The overall response rate of the treatment group was significantly higher than the control group in low risk and moderate risk patients (P=0.029)

there was no statistical differences of overall response rate between the treatment group and the control group in high risk patients (P=0.089). The expressions of CD13

CD14

CD33 and CD34 in all three risk levels of the treatment group were obviously decreased after the treatment

while CD15 in all three risk levels of the treatment group was obviously increased after the treatment (P<0.05 or P<0.01). Meanwhile

the difference values of CD13 and CD33 in low risk level of the treatment group

CD33 and CD34 in moderate risk level of the treatment group as well as CD34 and CD15 in high risk level of the treatment group

it is a feasible option in clinical practice.

关键词

myelodysplastic syndromeChinese Medicinepattern identificationimmunophenotype

Keywords

myelodysplastic syndromeChinese Medicinepattern identificationimmunophenotype

references

Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:831–841.

Santini V. Anemia as the main manifestation of myelodysplastic syndromes. Semin Hematol 2015;52:348–356.

Zhang Y, Qian LL, Ye BD, Zhou YH. Clinical observation of peripheral blood improving with myelodysplastic syndrome patient for traditional Chinese medcine. J Zhejiang Chin Med Univ (Chin) 2012;36:641–642.

Zhang ZN, Shen T, eds. Diagnostic and curative standard for blood diseases. 3rd ed. Beijing: Science Press; 2008:157–162.

Jonas BA, Greenberg PL. MDS prognostic scoring systemspast, present, and future. Best Pract Res Clin Haematol 2015;28:3–13.

Klepin HD. Myelodysplastic syndromes and acute myeloid leukemia in the elderly. Clin Geriatr Med 2016;32:155–173.

Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more. Curr Hematol Malig Rep 2010;5:9.

Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol 2016;27:62–68.

Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2015;90:969–983.

Sekeres MA, Gerds AT. Established and novel agents for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2014;2014:82–89.

Wu D, Du X, Jin J, Xiao Z, Shen Z, Shao Z, et al. Decitabine for treatment of myelodysplastic syndromes in chinese patients: an open-label, phase-3b study. Adv Ther 2015;32:1140–1159.

Inagaki S, Tamai Y, Yoshizawa M, Sato S, Kanbe E, Tanaka E. Unidentified inflammatory disease induced by azacitidine therapy for myelodysplastic syndrome. Cancer Chemotherapy (Japan) 2015;42:1443–1446.

Sekeres MA. Treatment of mds: something old, something new, something borrowed. Hematology Am Soc Hematol Educ Program 2009;2009:656–663.

Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling myelodysplastic syndromes: current knowledge and future directions. Curr Oncol Rep 2016;18:4.

Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:97–108.

Xu M, Lu JH. Research advances on pathogenesis of myelodysplastic syndrome. J Exp Hematol (Chin) 2015;23:1800–1807.

Gao J, Swaminathan S, Pai N, Johnson Z, Chen YH, Peterson L, et al. Flow cytometric detection of altered signaling in myelodysplastic syndrome and cytopenia. Leuk Res 2015;39:1396–1404.

Verigou E, Lampropoulou P, Smyrni N, Kolliopoulou G, Sakellaropoulos G, Starakis I, et al. Evaluation of a bone marrow dysmyelopoiesis immunophenotypic index for the diagnosis and prognosis of myelodysplastic syndromes. Cardiovasc Hematol Disord Drug Targets 2015;15:148–161.

Porwit A, Rajab A. Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of mds-related features. Int J Lab Hematol 2015;37:133–143.

Cremers EM, Alhan C, Westers TM, Ossenkoppele GJ, Van de Loosdrecht AA. Immunophenotyping for diagnosis and prognosis in MDS: ready for general application? Best Pract Res Clin Haematol 2015;28:14–21.

Heron M, Dovern E, Bakker-Jonges LE, Posthuma EF, Brouwer RE, Smedts F, et al. Translating the myelodysplastic syndrome flow cytometric score into clinical practice. Cytometry B Clin Cytom 2015;88:207–209.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

An innovative method to accommodate chinese medicine pattern diagnosis within the framework of evidence-based medical research

Standardization and future directions in pattern identification research: International brainstorming session

Acupuncture points used in the prophylaxis against recurrent uncomplicated cystitis, patterns identified and their possible relationship to physiological measurements

Current research and future directions in pattern identification: Results of an international symposium

Incorporating pattern identification of chinese medicine into precision medicine: An integrative model for individualized medicine

Related Author

No data

Related Institution

College of Traditional Chinese Medicine, Department of Medical and Molecular Biosciences, Faculty of Science

Mathematical Sciences, University of Technology

Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea

National Research Center in Complementary and Alternative Medicine, Department of Community Medicine, UiT The Artic University of Norway, Tromso

University College of Health Sciences, Campus Kristiania, Institute of Acupuncture

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰